Edition:
United States

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

2.80EUR
7:08am EST
Change (% chg)

€-0.01 (-0.36%)
Prev Close
€2.81
Open
€2.81
Day's High
€2.82
Day's Low
€2.79
Volume
28,358
Avg. Vol
84,613
52-wk High
€3.23
52-wk Low
€2.37

Chart for

About

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and... (more)

Overall

Beta: 1.86
Market Cap(Mil.): €218.01
Shares Outstanding(Mil.): 77.58
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 185.97 15.71
EPS (TTM): -- -- --
ROI: -- -11.84 31.93
ROE: -- -36.93 16.16

BRIEF-Valneva Expands Its Commercial Operations And Establishes US Infrastructure

* REG-VALNEVA EXPANDS ITS COMMERCIAL OPERATIONS AND ESTABLISHES US INFRASTRUCTURE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 30 2017

BRIEF-Valneva 9M EBITDA increases to 12.3 million euros

* TOTAL REVENUES OF €79.8 MILLION IN FIRST NINE MONTHS 2017 VERSUS TO €70.7 MILLION YEAR AGO‍​

Nov 09 2017

BRIEF-Valneva signs contract with US government

* ANNOUNCED ON TUESDAY SIGNATURE OF $39.6 MILLION IXIARO SUPPLY CONTRACT WITH US GOVERNMENT

Nov 08 2017

BRIEF-Valneva H1 EBITDA rises to 7.6 million euros

* ‍EBITDA INCREASED STRONGLY IN H1 2017 REACHING EUR 7.6 MILLION (VERSUS. EUR 4.7 MILLION IN H1 2016)​

Aug 31 2017

BRIEF-Valneva appoints David Lawrence as Chief Financial Officer

* LAWRENCE'S AND BENDER'S APPOINTMENTS BY THE COMPANY'S SUPERVISORY BOARD WILL BECOME EFFECTIVE ON AUGUST 7TH AND SEPTEMBER 1ST RESPECTIVELY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Aug 01 2017

BRIEF-Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

* Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

Jul 26 2017

BRIEF-Valneva receives FDA fast track designation for its lyme disease vaccine candidate VLA15

* REG-VALNEVA RECEIVES FDA FAST TRACK DESIGNATION FOR ITS LYME DISEASE VACCINE CANDIDATE VLA15

Jul 24 2017

BRIEF-Valneva confirms its growth strategy and R&D outlook

* REITERATES THAT IT EXPECTS REVENUES TO REACH EUR 105 TO EUR 115 MILLION IN 2017 AND EBITDA OF EUR 5 TO EUR 10 MILLION

Jun 30 2017

Earnings vs. Estimates